|
Koroukian, Siran M; Bakaki, Paul M; Golchin, Negar et al. (2015) Breast Cancer Stage and Treatment Among Ohio Medicaid Beneficiaries With and Without Mental Illness. J Oncol Pract 11:e50-8
|
|
Chandramohan, Vidyalakshmi; Mitchell, Duane A; Johnson, Laura A et al. (2013) Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 9:977-90
|
|
Chandramohan, Vidyalakshmi; Bao, Xuhui; Keir, Stephen T et al. (2013) Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 19:4717-27
|
|
Piao, Hailan; Kuan, Chien-Tsun; Chandramohan, Vidya et al. (2013) Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. MAbs 5:748-62
|
|
Chandramohan, Vidyalakshmi; Bao, Xuhui; Kato Kaneko, Mika et al. (2013) Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 132:2339-48
|
|
Reardon, David A; Desjardins, Annick; Peters, Katherine B et al. (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol 107:155-64
|
|
Reardon, David A; Desjardins, Annick; Vredenburgh, James J et al. (2012) Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 118:4759-67
|
|
Jiao, Yuchen; Killela, Patrick J; Reitman, Zachary J et al. (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709-22
|
|
Lou, Emil; Sumrall, Ashley L; Turner, Scott et al. (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109:63-70
|
|
Reardon, David A; Herndon 2nd, James E; Peters, Katherine et al. (2012) Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 107:213-21
|
Showing the most recent 10 out of 267 publications
